Cameron Petro-Sakur, DO
Internal Medicine · Salina, KSNPI 1093248668
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 311 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 20.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,531 and has fallen 54.2% since, to $701 in 2025. Among internal medicine clinicians in KS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 311 payments — averaging $16.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- Novo Nordisk$795
- Amgen$792
- AbbVie$766
- Biohaven Pharmaceuticals, Inc.$384
- Pfizer$256
- plus $1K from 23 others
What the payments were for
- Food & beverage$5,270100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 65 | $1,082 |
| Novo Nordisk | 45 | $795 |
| Amgen | 61 | $792 |
| AbbVie(2 entities) | 46 | $766 |
| Biohaven Pharmaceuticals, Inc. | 20 | $384 |
| Pfizer | 17 | $256 |
| Akcea Therapeutics, Inc. | 6 | $223 |
| Amarin Pharma, Inc. | 4 | $133 |
| GSK | 3 | $114 |
| AstraZeneca | 5 | $93 |
| Merck | 5 | $72 |
| Johnson & Johnson | 3 | $63 |
| Esperion Therapeutics, Inc. | 3 | $47 |
| Abbott | 2 | $43 |
| Bayer | 3 | $41 |
| Novartis | 3 | $41 |
| Chiasma, Inc. | 1 | $40 |
| Sanofi-aventis U.S. LLC | 2 | $36 |
| Boehringer Ingelheim | 2 | $34 |
| Eisai Inc. | 2 | $30 |
| Idorsia Pharmaceuticals US Inc | 2 | $28 |
| E.r. Squibb & Sons, L.L.C. | 2 | $28 |
| Kowa Pharmaceuticals America, Inc. | 2 | $27 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $26 |
| Radius Health, Inc. | 1 | $24 |
| Kyowa Kirin, Inc. | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Si-bone, Inc. | 1 | $17 |
| Astellas Pharma US Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,276 in reported general payments places this provider in the 90th percentile of 705 internal medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 539 | $558,663 |
| EliquisApixaban | 432 | $207,868 |
| OzempicSemaglutide | 148 | $144,302 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 174 | $115,250 |
| JardianceEmpagliflozin | 134 | $63,295 |
| XareltoRivaroxaban | 138 | $60,925 |
| OtezlaApremilast | 13 | $58,524 |
| FarxigaDapagliflozin Propanediol | 115 | $58,411 |
| VraylarCariprazine Hcl | 61 | $44,960 |
| TrulicityDulaglutide | 49 | $42,058 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 42 | $24,558 |
| MyrbetriqMirabegron | 51 | $23,989 |
| Tresiba Flextouch U-100Insulin Degludec | 40 | $17,673 |
| EntrestoSacubitril/Valsartan | 41 | $15,566 |
| Potassium Chloride | 385 | $13,826 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $1,082 | $600,721588 claims |
| PfizerEliquis | $256 | $207,868432 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $93 | $173,660289 claims |
| Novo NordiskOzempic | $795 | $144,302148 claims |
| Boehringer IngelheimJardiance, Tradjenta | $34 | $76,611165 claims |
| Johnson & JohnsonXarelto | $63 | $60,925138 claims |
| AmgenOtezla | $792 | $58,52413 claims |
| AbbVieVraylar, Linzess | $766 | $58,28484 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $114 | $43,98992 claims |
| Astellas Pharma US IncMyrbetriq | $12 | $23,98951 claims |
| NovartisEntresto | $41 | $15,56641 claims |
| MerckBelsomra | $72 | $10,60117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 705 internal medicine providers in Kansas.
Other internal medicine in Salina
- Shadi HamdehKansas City$959K
- Donna GriebelLawrence$781K
- Lucas PittsKansas City$235K
- Donna SweetWichita$185K
- Wissam SalibaWichita$155K
- Mark HamblinKansas City$147K
- Atieh JibbeWichita$121K
- Herbert WaxmanOverland Park$82K
- Aaron RohrKansas City$54K
- Raed Al RajabiWestwood$49K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.